Tagged with France

France Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses, playing host to virtually all top-tier, big-brand biopharma. Yet alongside its well-forged reputation for sophisticated healthcare infrastructure, manufacturing excellence, and…

France How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player which turns over around EUR 600 million annually – seems to have hit upon a solution: continuous adaptation.   “What…

France When Marc de Garidel joined AbiVax as CEO in 2023, the firm had very recently teetered on the brink of bankruptcy. Now, less than three short years later, he leads the hottest prospect in European biotech, with a potentially market-leading drug for inflammatory bowel disease nearing regulatory approval. de Garidel…

France France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability of France as an investment destination, although the reindustrialisation incentives contained with the ‘France 2030’ plan are leading to an…

France As global vaccine development grows more complex and capital more selective, Valneva is sharpening its identity and returning decisively to its roots. The company’s decision to close its Nantes site and re-centralise French operations in Lyon is more than operational streamlining; it signals a strategic recommitment to one of Europe’s…

France As metabolic liver disease rises rapidly up the global health agenda, Professor Cyrielle Caussy stands at the intersection of clinical care, translational research, and therapeutic innovation. A Professor of Nutrition at Lyon 1 University and endocrinologist-diabetologist at Hospices Civils de Lyon, Caussy is a leading voice in metabolic dysfunction-associated steatotic…

France Stéphane Legastelois has spent 35 years bridging science and business. After founding Indicia, he transitioned to healthcare investing, backing 30 early-stage companies, mainly in Lyon, and now heads up 33 Californie, a boutique investment firm which combines capital with strategic guidance, de-risking start-ups before Series A financing. As he explains,…

France Denmark and France are intensifying their cooperation in life sciences at a time when resilience, innovation and industrial capacity have become strategic priorities for Europe. In this interview, Hanne Fugl Eskjær, Denmark’s Ambassador to France, reflects on how complementary strengths in research, digital health and public-private collaboration are shaping a…

France Born from personal tragedy, Imagine for Margo has evolved into a pan-European force reshaping how childhood cancers are researched, funded, and brought to the policy agenda. Drawing on a parent’s perspective, Patricia Blanc explains how precision medicine, cross-border collaboration, and sustained advocacy can compress timelines and reduce inequality in rare…

France Raymond Le Moign leads one of Europe’s largest university hospital centres at a moment when healthcare systems are being forced to rethink how they organise care, innovation, and accountability. Drawing on experience that spans national health policy, oncology, regulation, and frontline hospital leadership, he lays out a long-term vision that…

France A new chapter in vital organ care is unfolding as Vantive establishes its identity as an independent, purpose-driven leader in kidney care. With Trushar Patel stepping into an expanded leadership role across Europe, the company is accelerating efforts to transform dialysis through home-based therapies, digital innovation and deeper partnerships with…

France Kyowa Kirin’s new head for France and Benelux steps into the role at a time when rare diseases, regulatory expectations and scientific modalities are all shifting at speed. In this interview, Aurelie-Anne Chausse reflects on the recent strategic transition toward a fully rare-disease-focused organisation, the growing pressure to identify patients…